A Single-Arm, Multicenter, Phase 2 Study of Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Brigatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Takeda
- 29 Jan 2018 New source identified and integrated (NCT03410108:ClinicalTrials.gov: US National Institutes of Health).
- 25 Jan 2018 Status changed from not yet recruiting to recruiting.
- 15 Jan 2018 New trial record